About ATP-dependent chromatin remodeler CHD2
ATP-dependent chromatin remodeler CHD2 (CHD2) is a protein
from Homo sapiens identified by UniProt accession
O14647, 1828 residues long.
MolForge cross-references it against 0 known binders and
245 disease associations.
Target properties
| Protein name | ATP-dependent chromatin remodeler CHD2 |
|---|
| UniProt accession | O14647 |
|---|
| Gene | CHD2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1828 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (245)
Diseases linked to this target (Open Targets).
- developmental and epileptic encephalopathy 94 · score 0.78
- chronic lymphocytic leukemia · score 0.71
- childhood-onset epilepsy syndrome · score 0.58
- complex neurodevelopmental disorder · score 0.57
- lymphoid leukemia · score 0.56
- Epileptic encephalopathy · score 0.56
- genetic disorder · score 0.55
- neurodegenerative disease · score 0.53
- Intellectual disability · score 0.52
- autism spectrum disorder · score 0.49
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O14647-F1 | alphafold | PREDICTED | 60.42 | — |
Amino-acid sequence (1828 residues)
MMRNKDKSQE EDSSLHSNAS SHSASEEASG SDSGSQSESE QGSDPGSGHG SESNSSSESS ESQSESESES AGSKSQPVLP EAKEKPASKK ERIADVKKMW EEYPDVYGVR RSNRSRQEPS RFNIKEEASS GSESGSPKRR GQRQLKKQEK WKQEPSEDEQ EQGTSAESEP EQKKVKARRP VPRRTVPKPR VKKQPKTQRG KRKKQDSSDE DDDDDEAPKR QTRRRAAKNV SYKEDDDFET DSDDLIEMTG EGVDEQQDNS ETIEKVLDSR LGKKGATGAS TTVYAIEANG DPSGDFDTEK DEGEIQYLIK WKGWSYIHST WESEESLQQQ KVKGLKKLEN FKKKEDEIKQ WLGKVSPEDV EYFNCQQELA SELNKQYQIV ERVIAVKTSK STLGQTDFPA HSRKPAPSNE PEYLCKWMGL PYSECSWEDE ALIGKKFQNC IDSFHSRNNS KTIPTRECKA LKQRPRFVAL KKQPAYLGGE NLELRDYQLE GLNWLAHSWC KNNSVILADE MGLGKTIQTI SFLSYLFHQH QLYGPFLIVV PLSTLTSWQR EFEIWAPEIN VVVYIGDLMS RNTIREYEWI HSQTKRLKFN ALITTYEILL KDKTVLGSIN WAFLGVDEAH RLKNDDSLLY KTLIDFKSNH RLLITGTPLQ NSLKELWSLL HFIMPEKFEF WEDFEEDHGK GRENGYQSLH KVLEPFLLRR VKKDVEKSLP AKVEQILRVE MSALQKQYYK WILTRNYKAL AKGTRGSTSG FLNIVMELKK CCNHCYLIKP PEENERENGQ EILLSLIRSS GKLILLDKLL TRLRERGNRV LIFSQMVRML DILAEYLTIK HYPFQRLDGS IKGEIRKQAL DHFNADGSED FCFLLSTRAG GLGINLASAD TVVIFDSDWN PQNDLQAQAR AHRIGQKKQV NIYRLVTKGT VEEEIIERAK KKMVLDHLVI QRMDTTGRTI LENNSGRSNS NPFNKEELTA ILKFGAEDLF KELEGEESEP QEMDIDEILR LAETRENEVS TSATDELLSQ FKVANFATME DEEELEERPH KDWDEIIPEE QRKKVEEEER QKELEEIYML PRIRSSTKKA QTNDSDSDTE SKRQAQRSSA SESETEDSDD DKKPKRRGRP RSVRKDLVEG FTDAEIRRFI KAYKKFGLPL ERLECIARDA ELVDKSVADL KRLGELIHNS CVSAMQEYEE QLKENASEGK GPGKRRGPTI KISGVQVNVK SIIQHEEEFE MLHKSIPVDP EEKKKYCLTC RVKAAHFDVE WGVEDDSRLL LGIYEHGYGN WELIKTDPEL KLTDKILPVE TDKKPQGKQL QTRADYLLKL LRKGLEKKGA VTGGEEAKLK KRKPRVKKEN KVPRLKEEHG IELSSPRHSD NPSEEGEVKD DGLEKSPMKK KQKKKENKEN KEKQMSSRKD KEGDKERKKS KDKKEKPKSG DAKSSSKSKR SQGPVHITAG SEPVPIGEDE DDDLDQETFS ICKERMRPVK KALKQLDKPD KGLNVQEQLE HTRNCLLKIG DRIAECLKAY SDQEHIKLWR RNLWIFVSKF TEFDARKLHK LYKMAHKKRS QEEEEQKKKD DVTGGKKPFR PEASGSSRDS LISQSHTSHN LHPQKPHLPA SHGPQMHGHP RDNYNHPNKR HFSNADRGDW QRERKFNYGG GNNNPPWGSD RHHQYEQHWY KDHHYGDRRH MDAHRSGSYR PNNMSRKRPY DQYSSDRDHR GHRDYYDRHH HDSKRRRSDE FRPQNYHQQD FRRMSDHRPA MGYHGQGPSD HYRSFHTDKL GEYKQPLPPL HPAVSDPRSP PSQKSPHDSK SPLDHRSPLE RSLEQKNNPD YNWNVRKT
Explore ATP-dependent chromatin remodeler CHD2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets